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Draft Genome Sequence of Photobacterium halotolerans S2753,
Producer of Bioactive Secondary Metabolites
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We report here the whole draft genome sequence of marine isolate Photobacterium halotolerans S2753, which produces the
known antibiotic holomycin and also ngercheumicins and solonamides A and B, which interfere with virulence of methicillin-
resistant Staphylococcus aureus strains by interacting with the quorum-sensing system.
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Photobacterium halotolerans strain S2753 is a Gram-negativemarine bacterium that was isolated from a mussel during the
Danish global expedition Galathea 3 (1). It is able to inhibit the
growth of bothGram-positive andGram-negative pathogens such
as Staphylococcus aureus (human pathogen) and Vibrio anguilla-
rum (fish pathogen) (1, 2). This specific strain has been shown to
produce a variety of secondary metabolites with distinct bioactiv-
ities (3, 4). It produces holomycin, a known antibiotic (2), as well
as a series of ngercheumicin analogues (5) (K. Adachi, Y. Kawa-
bata, H. Kasai, M. Katsuta, and Y. Shizuri, 13 September 2007,
Japanese patent application JP 2007–230911A) andmost interest-
ingly two novel cyclodepsipeptides named solonamide A and
solonamide B (3, 4).
Antimicrobial resistance in pathogens is a serious problem de-
rived both from the rapid adaptation of microorganisms to anti-
microbials and the recent stagnancy in antibiotic discovery. S. au-
reus is a versatile pathogen that has caused particular concern
recently due to fast antimicrobial resistance development among
both clinical and community isolates (6–8). Therefore, therapeu-
tics that do not exert a killing effect, but rather interfere with
virulence of the organism, e.g., by interfering with the quorum-
sensing systems, have been studied and developed in recent years
(9). P. halotolerans S2753 produces compounds capable of reduc-
ing the expression of virulence in S. aureus (10). Both the
ngercheumicins and solonamides interfere with the Agr system of
S. aureus, with solonamideBhaving the strongest interaction (10).
Also, this compound can compete with the four classes of autoin-
ducing peptides (AIPs) in S. aureus, although interference with
AIP class III is weak.
This announcement reports the draft genome sequence of
P. halotolerans S2753, a strain producing chemical compounds
with interesting features for application in biotechnological and
medical fields.
High-purity genomicDNAwas extracted by successive phenol:
chloroform:isoamyl-alcohol purification steps followed by pre-
cipitation with isopropanol, treatment with RNase, and final pu-
rification and precipitation steps (11). Quantification was done in
1% agarose gel electrophoresis using a NanoDrop spectrometer
(Saveen Werner, Sweden) and Qubit 2.0 analyzer (Invitrogen,
United Kingdom).
The sequencing of the genomes was performed by the Beijing
Genomic Institute (Shenzhen, China). Libraries of 500 bp were
used for 100-bp paired-end sequencing of genomes using Illu-
mina sequencing technology on an HiSeq2000 with a minimum
coverage of 100. This generated 5.03 million reads of clean data,
making a total of 462,754,934 bases. The data were assembled into
82 contigs (200 bp) covering 4,533,138 bases by de novo assem-
bly in CLC Genomic Workbench, version 7 (CLC Bio, Aarhus,
Denmark).
In order to predict clusters involved in secondary metabolite
synthesis, the reported genome was run on the analysis pipeline
antiSMASH (12,13), revealing the potential of this specific strain.
Besides the holomycin cluster, 11 other putative clusters encoding
secondary metabolites were identified in the P. halotolerans S2753
genome.
Nucleotide sequence accessionnumbers.Thiswhole-genome
shotgun project has been deposited at DDBJ/EMBL/GenBank un-
der the accession no. JMIB00000000. The version described in this
paper is version JMIB01000000.
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